Marc Rubin
CIK 1412377 · Executive Chairman · last filed 2026-07-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GALT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
400 OYSTER POINT BLVD., STE 505
SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRIS | Director | 1,405 | $0.38 | $530 | $55.3K | 23 | 2026-07-09 |
| GALT | Director | 13,581 | $3.19 | $43.3K | -$713.8K | 13 | 2025-01-27 |
| TITAN PHARMACEUTICALS INC (TTNP) Delisted | Executive Chairman | 155 | $4.61 | $715 | $116.2K | 10 | 2022-01-05 |
| GALECTIN THERAPEUTICS INC (GALTW) Delisted | Director | 17,446 | — | — | $26.1K | 4 | 2016-12-19 |
| MEDX | Director | — | $36.66 | — | $0 | 3 | 2009-03-09 |
| TITAN PHARMACEUTICALS INC (TTP) Delisted | President & Chief Ex Officer | 132,500 | $47.61 | $6.31M | $40.0K | 4 | 2008-10-22 |
Recent Filings · Page 5 of 7
68 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-08-31 | — | Buy (P) | +50,000 | $35.8K | |
| 2015-07-08 | GALECTIN THERAPEUTICS INC (GALTW) Delisted | Mixed | +42,247 | $0 | EDGAR |
| 2015-03-18 | — | Grant (A) | — | $0 | |
| 2015-01-28 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2014-10-14 | — | Buy (P) | +100,000 | $48.2K | |
| 2014-02-14 | — | Grant (A) | +100,000 | $66.0K | |
| 2014-01-28 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2013-12-04 | GALECTIN THERAPEUTICS INC (GALTW) Delisted | Buy (P) | +3,000 | $26.1K | EDGAR |
| 2013-06-19 | — | Buy (P) | +50,000 | $22.7K | |
| 2013-04-01 | GALECTIN THERAPEUTICS INC (GALTW) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.